CNS Stimulant
ApprovedSmall molecule
CNS Stimulant is one of 19 small molecule programs targeting Irritability. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Irritability
#DrugCompanyPhaseTrials
1Robitussin
PfizerApproved
Aricept
EisaiApproved
Calciferol
Alnylam PharmaceuticalsApproved
Chantix
PPrism Pharmaceuticals
Approved
Abilify
OtsukaApproved
Prometrium
FerringApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Risperdal
WWim Janssens
Phase 3
Karx-EC
Bristol-Myers SquibbPhase 3
Karxt
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CNS Stimulant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMilton S. Hershey Medical Center